OPTIMIZING THE USE OF RISK FACTORS TO GUIDE THE COST-EFFECTIVE USE OF PALIVIZUMAB PROPHYLAXIS AGAINST SEVERE RESPIRATORY SYNCYTIAL VIRUS INFECTION IN KOREAN INFANTS BORN 32-35 WEEKS' GESTATIONAL AGE

被引：0
|
作者：
Keary, I [1 ]
Kang, J. M. [2 ]
Paes, B. [3 ]
Rodgers-Gray, B.
Fullarton, J. [1 ]
Tarride, J. E.
Yang, H. J. [4 ]
Chang, Y. S. [5 ]
Carbonell-Estrany, X. [6 ]
机构：
[1] Violicom Med Ltd, Reading, Berks, England
[2] Yonsei Univ, Severance Childrens Hosp, Coll Med, Seoul, Gyeonggi, South Korea
[3] McMaster Univ, Hamilton, ON, Canada
[4] Soonchunhyang Univ Seoul Hosp, Seoul, Gyeonggi, South Korea
[5] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, Gyeonggi, South Korea
[6] Hosp Clin Barcelona, Barcelona, Spain
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE390
引用
收藏
页码：S125 / S125
页数：1
相关论文
共 31 条
  • [21] Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age
    X. Carbonell-Estrany
    L. Bont
    G. Doering
    J-B. Gouyon
    M. Lanari
    European Journal of Clinical Microbiology & Infectious Diseases, 2008, 27
  • [22] Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age
    Carbonell-Estrany, X.
    Bont, L.
    Doering, G.
    Gouyon, J-B
    Lanari, M.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2008, 27 (10) : 891 - 899
  • [23] COST EFFECTIVENESS OF PALIVIZUMAB FOR RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS AMONG EXTREME PRETERM INFANTS (29 WEEKS OF GESTATIONAL AGE) AT THE SOCIAL SECURITY MEXICAN INSTITUTE (IMSS)
    Paladio Hernandez, J. A.
    Lagunas-Quiroz, J., I
    Matias-Juan, N. A.
    VALUE IN HEALTH, 2020, 23 : S156 - S156
  • [24] An update of the recommendations of the Spanish Neonatology Society for the use of palivizumab as prophylaxis for severe infections due to syncytial respiratory virus in high risk infants
    Sanchez Luna, Manuel
    Perez Munuzuri, Alejandro
    Leante Castellanos, Jose Luis
    Ruiz Campillo, Cesar W.
    Sanz Lopez, Ester
    Benavente Fernandez, Isabel
    Sanchez Redondo, Maria Dolores
    Rite Gracia, Segundo
    ANALES DE PEDIATRIA, 2019, 91 (05): : 348 - 350
  • [25] Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain
    Figueras-Aloy, J
    Carbonell-Estrany, X
    Quero, J
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2004, 23 (09) : 815 - 820
  • [26] European risk factors' model to predict hospitalization of premature infants born 33-35 weeks' gestational age with respiratory syncytial virus: validation with Italian data
    Simoes, Eric A. F.
    Carbonell-Estrany, Xavier
    Fullarton, John R.
    Rossi, Giovanni A.
    Barberi, Ignazio
    Lanari, Marcello
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2011, 24 (01): : 152 - 157
  • [27] Cost-effectiveness of respiratory syncytial virus prophylaxis in premature infants less than 32 weeks gestational age in Turkey: author's reply
    Oncel, Mehmet Yekta
    Alyamac-Dizdar, Evrim
    Erdeve, Omer
    Oguz, Suna
    Dilmen, Ugur
    TURKISH JOURNAL OF PEDIATRICS, 2013, 55 (05) : 568 - 568
  • [28] Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33-35 Weeks Gestational Age in Quebec A Multicenter Retrospective Study
    Papenburg, Jesse
    Saleem, Mahwesh
    Teselink, Johannes
    Li, Abby
    Caouette, Georges
    Masse, Edith
    Lanctot, Krista L.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2020, 39 (08) : 694 - 699
  • [29] Commentary: The unresolved issue of risk factors for hospitalization of infants with respiratory syncytial virus infection born after 33-35 weeks gestation
    Meissner, HC
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2004, 23 (09) : 821 - 823
  • [30] Prevalence of Respiratory Syncytial Virus (RSV) Risk Factors and Cost Implications of Immunoprophylaxis to Infants 32 to 35 Weeks Gestation for Health Plans in the United States
    Krilov, Leonard R.
    Palazzi, Debra L.
    Fernandes, Ancilla W.
    Klein, Robert W.
    Mahadevia, Parthiv J.
    VALUE IN HEALTH, 2010, 13 (01) : 77 - 86
1234